期刊文献+

RNAi-chk1在抑制小鼠Lewis肺癌细胞生长作用的实验研究

Suppression of The mouse Lewis lung cancer cell growth induced by siRNA-chk1 combined radiotherapy
下载PDF
导出
摘要 目的观察chk1-RNAi联合放疗对Lewis肺癌细胞的抑制及凋亡情况。方法以脂质体Lipofectimine-2000介导,将chk1-536的siRNA表达载体转染小鼠Lewis肺癌细胞株,将其分为空白对照组、错义序列组、siRNA组,2Gy照射组、2Gy照射+错义序列组、2Gy照射+siRNA组。应用MTT法检测转染细胞抑制率、流式细胞术分析转染siRNA后细胞的凋亡,并应用RT-PCR检测转染细胞chk1-mRNA表达水平。结果 chk1-siRNA转染联合辐射组的Lewis肺癌细胞,与对照组相比较生长增殖受抑制、细胞凋亡增加;MTT法检测和流式细胞术分析示:chk1-siRNA转染联合辐射组的Lewis肺癌细胞生长增殖受抑制,细胞凋亡增加(P<0.05);同时,RT-PCR法检测该组细胞中chk1mRNA表达量下降(P<0.05)。并且siRNA转染可增加2Gy照射引起的Lewis肺癌细胞凋亡。结论针对chk-1的RNAi可以提高Lewis肺癌细胞的抑制率及放疗引起的肿瘤细胞的凋亡,对肿瘤有治疗作用,与放疗有协同作用。 Objective To observe the suppression and apoptosis of the Lung cancer Lewis cell by siRNA-chk1 combined radiotherapy.Methods It carried the chk1 siRNA gene into mouse Lewis lung cancer cell lines in vitro through Lipofectimine?2000.We devide into a control group、scrambled sequence group、siRNA group、2Gy radiation group、2Gy radiation + scrambled sequence group and2Gy radiation +siRNA group.The inhibited rate of transfected cells were observed by MTT assay,cell apoptosis were observed by flow cytometry,expression of chk1 were analysised by immunohistochemical.Results Compared with control group,the cells of chk1-siRNA combined radiotherapy were slower,but apoptosis on the contrary.MTT method and FCM showed that more Lewis cells proliferated effectively slowlier and apoptosis induced with chk1 siRNA combined radiotherapy(P〈0.05).And then the expression of chk1 of that group significantly decreased at protein level in vitro(P〈0.05).Conclusion The chk1-RNAi can enhance inhibition of Lewis lung cancer cells and the cell apoptosis induced radiotherapy.They has therapeutic effects on the tumor and has synergistic effect with radiation therapy.
出处 《中国实验诊断学》 2012年第9期1583-1585,共3页 Chinese Journal of Laboratory Diagnosis
关键词 RNA干扰 ADP核糖转移酶类 放射疗法 抑瘤作用 RNA interference(RNAi) checkpoint kinase1 radiotherapy anti-tumor effect
  • 相关文献

参考文献12

  • 1Bartek J ,Lukas J. Chkl and Chk2 kinases in checkpoint control and cancer[,J]. Cancer Ce11,2003,3 (5) :421.
  • 2Zhou BB, Sausville EA. Drug discovery targeting Chkland Chk2 kinases[,J]. Prog Cell Cycle Res, 2003,5 : 413.
  • 3Ponder BA. Cancer genetics[J]. Nature,2001,411(6835) ,336.
  • 4Khanna KK,Jaeson SP. DNA double stand breaks., signaling,repair and the cancer connection[J]. Natuere Genetic, 2001,27,247.
  • 5王铁君,郭喜平,董丽华,韩成敏.小鼠Chk1基因RNAi表达质粒的构建与筛选[J].中国生物制品学杂志,2009,22(4):359-362. 被引量:1
  • 6Robinson HM, Black EJ, Brown R, et al. DNA mismatch repair and Chkl-dependent centrosome amplification in response to DNA alkylation damage[,J]. Cell Cycle, 2007,6 (8): 982.
  • 7Tao ZF, Lin NH. Chkl inhibitors for novel cancer treatment [J]. Anticancer Agents Meal Chem, 2006,6 (4) : 377.
  • 8Petridou E,Belechri M,Dessypris N, et al. Leptin and body mass index in relation to endomet rial cancer risk [J]. Ann Nutr Metab, 2002,46 (3/4): 147.
  • 9Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells[J]. Nature, 2002, 418(6896) : 430.
  • 10Carthew RW. RNA interference: the fragile X-syndrome con- nection[J]. Curt Biol, 2002,12 (24) : 852.

二级参考文献1

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部